A Phase 3 interventional study of Nilotinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 3rd largest by enrollment, is one of 6 that started in 2008, is one of 4 in phase 3, and was the 12th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2008.
This study's enrollment of 125 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 35 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 3 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
27 studies in Gastrointestinal Stromal Tumors by Novartis: none open now, none under way, none of them phase 3. Of 26 finished, 14 (54%) have results posted.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 8th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2008, is one of 4 in phase 3, and was the 18th registered.
Novartis’s Gastrointestinal Stromal Tumors studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 27 in Gastrointestinal Stromal Tumors:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
nilotinib 400 mg twice daily (bid).
Drug: Nilotinib
Also known as: AMN107
Percent of Patients Achieving Stable Disease (SD)
Neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Progression Disease, taking as reference the smallest sum of the longest diameter since the treatment started.
Time frame: During the first 4 months
Percent of Patients Achieving Partial Response (PR)
The primary efficacy variable was defined as the proportion of patients with a best overall response of CR by Week 16/Month 4 based on local assessment according to RECIST (Version 1.0). This is an at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
Time frame: during the first 4 months
Percent of Patients Achieving Complete Response (CR)
Complete response (CR) is the Disappearance of all target lesions.
Time frame: during the first 4 months
Analysis of Time to Overall Response (CR or PR) According to RECIST Using Kaplan-Meier Method for ITT Population
Complete Response (CR): Disappearance of all target lesions. and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
Time frame: 24 weeks and 52 weeks
Time to Overall Response (CR or PR): Per Protocol Population
Complete Response (CR): Disappearance of all target lesions, and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
Time frame: 24 weeks and 52 weeks
Time to Tumor Progression
Time to tumor progression defined as the time from start of treatment to observed tumor progression (censoring for death without progression) as stated in the original protocol was not evaluated as stated in section 9.8.3 of the clinical study report.
Time frame: during the first 4 months
Duration of Overall Response
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence
Time frame: during 12 months
Overall Survival, Number of Events Related to Progression of the Disease
The OS rate could not be calculated due to the high number of censored cases. Number of censored, n (%) 108 (86.4). Only available data is number of events. OS was defined as the time from first study drug administration to death from any cause. If a patient was not known to have died, survival was censored at date of last contact.
Time frame: during 12 months
Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment.
Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.
Time frame: during 12 months
| Milestone | Nilotinib |
|---|---|
| Started | 125 |
| Completed | 42 |
| Not completed | 83 |
| Withdrew: Progressive disease | 49 |
| Withdrew: Adverse event | 14 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Death | 4 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: No longer required | 2 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: New cancer therapy | 2 |
| Withdrew: Abnormal lab value | 1 |
| Withdrew: Missing reason for discon | 1 |
Neither sufficient shrinkage to qualify for Partial Response nor sufficient increase to qualify for Progression Disease, taking as reference the smallest sum of the longest diameter since the treatment started.
| % participants | Nilotinib |
|---|---|
| Percent of Patients Achieving Stable Disease (SD) | 48.8 |
The primary efficacy variable was defined as the proportion of patients with a best overall response of CR by Week 16/Month 4 based on local assessment according to RECIST (Version 1.0). This is an at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
| percentage of participants | Nilotinib |
|---|---|
| Percent of Patients Achieving Partial Response (PR) | 0 |
Complete response (CR) is the Disappearance of all target lesions.
| percentage of participants | Nilotinib |
|---|---|
| Percent of Patients Achieving Complete Response (CR) | 0 |
Complete Response (CR): Disappearance of all target lesions. and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
| percentage of participants | Nilotinib |
|---|---|
| 24 weeks | 92.0 |
| 52 weeks | 92.0 |
Complete Response (CR): Disappearance of all target lesions, and Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.
| percentage of participants | Nilotinib |
|---|---|
| 24 weeks | 91.2 |
| 52 weeks | 91.2 |
Time to tumor progression defined as the time from start of treatment to observed tumor progression (censoring for death without progression) as stated in the original protocol was not evaluated as stated in section 9.8.3 of the clinical study report.
No measurements were reported for this outcome.
The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence
| days | Nilotinib |
|---|---|
| Duration of Overall Response | 1331 (366 to NA) |
The OS rate could not be calculated due to the high number of censored cases. Number of censored, n (%) 108 (86.4). Only available data is number of events. OS was defined as the time from first study drug administration to death from any cause. If a patient was not known to have died, survival was censored at date of last contact.
| events | Nilotinib |
|---|---|
| Overall Survival, Number of Events Related to Progression of the Disease | 17 |
Progression-free survival (PFS) is defined as the time from first study drug administration to objective tumor progression or death from any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.
| days | Nilotinib |
|---|---|
| Progression Free Survival (PFS) of the Patients Who Were Included Due to an Intolerability of a Prior Treatment. | 110 (64 to 118) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Patients | — | 60/125 (48%) | 107/125 (85.6%) |
| Event | All Patients |
|---|---|
| Abdominal painGastrointestinal disorders | 7/125 |
| AnaemiaBlood and lymphatic system disorders | 6/125 |
| Disease progressionGeneral disorders | 6/125 |
| VomitingGastrointestinal disorders | 5/125 |
| PyrexiaGeneral disorders | 5/125 |
| ConstipationGastrointestinal disorders | 3/125 |
| FatigueGeneral disorders | 3/125 |
| General physical health deteriorationGeneral disorders | 3/125 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/125 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/125 |
| Event | All Patients |
|---|---|
| FatigueGeneral disorders | 44/125 |
| ConstipationGastrointestinal disorders | 32/125 |
| Abdominal painGastrointestinal disorders | 28/125 |
| NauseaGastrointestinal disorders | 28/125 |
| VomitingGastrointestinal disorders | 21/125 |
| PruritusSkin and subcutaneous tissue disorders | 21/125 |
| PyrexiaGeneral disorders | 19/125 |
| DiarrhoeaGastrointestinal disorders | 18/125 |
| Decreased appetiteMetabolism and nutrition disorders | 18/125 |
| Oedema peripheralGeneral disorders | 17/125 |
| Age, Continuous(years) | Nilotinib |
|---|---|
| Mean | 60 ± 12.1 |
| Gender(Participants) | Nilotinib |
|---|---|
| Female | 46 |
| Male | 79 |
The record gives a start of Nov 2008, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Gastrointestinal Stromal Tumors →